Literature DB >> 31376088

Systemic sclerosis and urinary symptoms: a complex pathophysiology.

Gregor John1,2,3.   

Abstract

Lower urinary tract symptoms (LUTS) have long been overlooked in systemic sclerosis (SSc). However, they are out of proportion of what would be expected based on age, sex, and presence of usual risk factors. Thus, there must be specific scleroderma-related mechanisms to result in LUTS. Fibrosis, nervous involvement (notably, dysautonomia), early signs of menopauses, and functional restriction play certainly a role, but available evidence shows inconsistent results. Thus, these factors are not sufficient to explain all aspect of LUTS in SSc. In vitro experiments point out a promising alternative mechanism, already observed in other rheumatologic diseases: an antibody-mediated etiology. However, more research is needed to better understand the pathophysiology of LUTS in SSc and develop specific treatment.

Entities:  

Keywords:  Antibodies; Fibrosis; Pathophysiology; Systemic sclerosis; Urinary incontinence

Year:  2019        PMID: 31376088     DOI: 10.1007/s10067-019-04714-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  M(3) muscarinic receptors mediate contraction of human urinary bladder.

Authors:  Charlotte Fetscher; Marina Fleichman; Martina Schmidt; Susanne Krege; Martin C Michel
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

2.  Scleroderma; based on a study of over 150 cases.

Authors:  I LEINWAND; A W DURYEE; M N RICHTER
Journal:  Ann Intern Med       Date:  1954-11       Impact factor: 25.391

3.  Scleroderma of lower urinary tract.

Authors:  S Raz; R Boxer; J Waisman; R J Sukov
Journal:  Urology       Date:  1977-06       Impact factor: 2.649

4.  Prevalence and Disease-Specific Risk Factors for Lower Urinary Tract Symptoms in Systemic Sclerosis: An International Multicenter Study.

Authors:  Gregor John; Jérôme Avouac; Silvia Piantoni; Pamela Polito; Micaela Fredi; Franco Cozzi; Paolo Airò; Marie-Elise Truchetet; Franco Franceschini; Yannick Allanore; Carlo Chizzolini
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-06-19       Impact factor: 4.794

5.  Collagen in 155 human bladders.

Authors:  J G Susset; D Servot-Viguier; F Lamy; P Madernas; R Black
Journal:  Invest Urol       Date:  1978-11

6.  Passive transfer of Sjogren's syndrome IgG produces the pathophysiology of overactive bladder.

Authors:  Fang Wang; Michael W Jackson; Vicki Maughan; Dana Cavill; Anthony J Smith; Sally A Waterman; Tom P Gordon
Journal:  Arthritis Rheum       Date:  2004-11

7.  Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells.

Authors:  Jagmohan Singh; Vaibhav Mehendiratta; Francesco Del Galdo; Sergio A Jimenez; Sidney Cohen; Anthony J DiMarino; Satish Rattan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-09-24       Impact factor: 4.052

Review 8.  The autonomic nervous system in systemic sclerosis. A review.

Authors:  Luca Bertinotti; Stefania Bracci; Francesca Nacci; Nicola Colangelo; Angela Del Rosso; Roberto Casale; Alberto Pignone; Marco Matucci-Cerinic
Journal:  Clin Rheumatol       Date:  2003-12-10       Impact factor: 2.980

Review 9.  Severe urinary bladder involvement in systemic sclerosis. Case report and review of the literature.

Authors:  L La Civita; L Fiorentini; A Tognetti; G Pasero; C Ferri
Journal:  Clin Exp Rheumatol       Date:  1998 Sep-Oct       Impact factor: 4.473

10.  Vesical dysfunction in systemic sclerosis (scleroderma)

Authors:  M Lazzeri; P Beneforti; G Benaim; C Corsi; V Ciambrone; E Marrapodi; G Mincione; D Turini
Journal:  J Urol       Date:  1995-04       Impact factor: 7.450

View more
  1 in total

1.  Urinary incontinence in systemic sclerosis: a prospective multicentre cohort study.

Authors:  Gregor John; Elisabetta Zanatta; Pamela Polito; Silvia Piantoni; Micaela Fredi; Yann Coattrenec; Romain Guemara; Franco Franceschini; Marie-Elise Truchetet; Franco Cozzi; Paolo Airò; Carlo Chizzolini
Journal:  Rheumatol Int       Date:  2022-08-09       Impact factor: 3.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.